Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
暂无分享,去创建一个
Gavin Giovannoni | Xavier Montalban | Ernst-Wilhelm Radue | Jitesh Rana | Ralf Gold | Randy Robinson | X. Montalban | E. Radue | R. Gold | E. Havrdová | G. Giovannoni | K. Selmaj | J. Elkins | Krzysztof Selmaj | Eva Havrdova | Dusan Stefoski | Randy R. Robinson | G. O'neill | D. Stefoski | Katherine Riester | Jacob Elkins | J. Rana | Gilmore O'Neill | K. Riester
[1] T. Waldmann,et al. A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy , 2011, Nature Medicine.
[2] Matthew Hardy,et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource , 2009, Nature Genetics.
[3] A Thompson,et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. , 2001, Brain : a journal of neurology.
[4] J. Ware,et al. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.
[5] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[6] A. DeMichele,et al. CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients , 2012, Science Translational Medicine.
[7] R. Zinkernagel,et al. Immune responses in interleukin-2-deficient mice. , 1993, Science.
[8] Xavier Montalban,et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta , 2010, The Lancet Neurology.
[9] Linjiang Zhu,et al. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. , 2009, Immunity.
[10] J. Rose,et al. Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody , 2004, Annals of neurology.
[11] A. Williams. EuroQol : a new facility for the measurement of health-related quality of life , 1990 .
[12] H. Weiner,et al. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions , 1986, Annals of neurology.
[13] C. Poser,et al. Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.
[14] B. Bielekova,et al. Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis , 2012, Science Translational Medicine.
[15] T. Waldmann,et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[16] E. Jacquemin,et al. CD25 Appears Non Essential for Human Peripheral Treg Maintenance In Vivo , 2010, PloS one.
[17] F. Shi,et al. Interleukin‐2/interleukin‐2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation , 2011, Annals of neurology.
[18] C. Polman,et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis , 2011, Multiple sclerosis.
[19] P. Matthews,et al. Normalized Accurate Measurement of Longitudinal Brain Change , 2001, Journal of computer assisted tomography.
[20] L. Roccatagliata,et al. Surrogate endpoints for EDSS worsening in multiple sclerosis , 2010, Neurology.
[21] Donna Graves,et al. Current and emerging therapies in multiple sclerosis: a systematic review , 2012, Therapeutic advances in neurological disorders.
[22] C. Lederer,et al. Disability as an outcome in MS clinical trials , 2008, Neurology.
[23] T. Malek,et al. The biology of interleukin-2. , 2008, Annual review of immunology.
[24] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[25] H. McFarland,et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. , 2009, Archives of neurology.
[26] T. Waldmann,et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[27] J. Sheridan,et al. Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis , 2011, Multiple sclerosis.
[28] H. Rodt,et al. Immunohistochemical identification of T-lymphocytes in the central nervous system of patients with multiple sclerosis and subacute sclerosing panencephalitis , 1982, Journal of Neuroimmunology.
[29] F. Lublin. The incomplete nature of multiple sclerosis relapse resolution , 2007, Journal of the Neurological Sciences.
[30] B. Bielekova,et al. An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2–Driven Activation of CD56bright NK Cells , 2010, The Journal of Immunology.